文献速递艾滋病与性传播感染

维生素D和钙补充对泰国围产期感染HIV青少年骨密度与骨代谢的影响:一项随机临床试验

Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该多中心随机开放标签主动对照试验纳入200例10-20岁稳定cART的围产期HIV感染泰国青少年,比较标准剂量与高剂量维生素D/钙补充48周对腰椎骨密度和骨代谢的影响。两组腰椎骨密度均显著升高,高剂量组z评分改善更明显,骨代谢标志物在两组均显著下降。

要点

  • 48周维生素D/钙补充使两组腰椎骨密度均显著升高。
  • 高剂量组腰椎骨密度z评分改善显著优于标准剂量组。
  • 高剂量维生素D/钙补充或可考虑用于促进该人群骨健康。

核心结论

  • 48周维生素D/钙补充后两组腰椎骨密度显著升高、骨代谢标志物显著下降。
  • 高剂量组腰椎骨密度z评分改善优于标准剂量组。
  • 高剂量维生素D/钙补充或可考虑用于促进该人群骨健康。

研究设计与样本

  • 多中心、随机、主动对照、开放标签试验,纳入200例10-20岁稳定cART的围产期HIV感染泰国青少年。
  • 按基线腰椎骨密度分层,1:1随机分配至标准剂量或高剂量维生素D/钙补充48周。

主要发现

  • 高剂量组腰椎骨密度中位增加0.07 g/cm2(IQR +0.04至+0.11,P < .001)。
  • 标准剂量组腰椎骨密度中位增加0.09 g/cm2(IQR +0.03至+0.13,P < .001)。
  • 高剂量组腰椎骨密度z评分中位变化+0.4(IQR -0.1至+0.9),标准剂量组+0.1(IQR -0.4至+0.7),P = .02。
  • 两组25(OH)D升高,iPTH、CTX、PINP显著下降(P < .05),组间无差异。

关键数值与推荐

  • 基线腰椎骨密度低定义为z-score ≤ -2,正常为> -2。
  • 标准剂量为400 IU/1200 mg/天,高剂量为400 IU/1200 mg/天加麦角钙化醇20 000 IU/周。

临床怎么用

  • 对该人群可考虑高剂量维生素D/钙补充以改善腰椎骨密度z评分。
  • 补充期间应监测腰椎骨密度及骨代谢标志物变化。

局限性

  • 开放标签设计可能引入偏倚。
  • 仅纳入泰国围产期HIV感染青少年,外推需谨慎。
  • 随访48周,长期骨骼结局未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the impact of vitamin D and calcium supplementation (VitD/Ca) on lumbar spine bone mineral density (LSBMD) and bone metabolism among Thai adolescents with perinatally acquired HIV (PHIVA). METHODS: A multicenter, randomized, active-control, open-labeled trial was conducted. PHIVA (aged 10-20 years) who were on stable cART were enrolled. Baseline LSBMD status was defined as low (z-score ≤ -2) and normal (> -2). Eligible PHIVA were randomly assigned to receive standard-dose (400 IU/1200 mg/day) or high-dose (400 IU/1200 mg/day plus ergocalciferol 20 000 IU/week) VitD/Ca supplementation for 48 weeks (ratio 1:1, stratified by baseline LSBMD). Study outcomes were changes in LSBMD, LSBMD z-scores, and bone metabolism-related biomarkers (25-hydroxyvitamin D [25(OH)D], intact parathyroid hormone [iPTH], C-terminal telopeptide [CTX], procollagen type I amino-terminal propeptide [PINP]) from baseline to week 48. RESULTS: Among 200 enrolled PHIVA, median age was 16 (IQR:14-18) years; 61% were on NNRTI-based cART. Median 25(OH)D level was 25.5 (IQR: 20.8-33.0) ng/mL. After 48-week VitD/Ca supplementation, LSBMD significantly increased in both treatment groups (high-dose: median: +0.07 [IQR: +0.04 to +0.11] g/cm2; P < .001; standard-dose: +0.09 [+0.03 to +0.13] g/cm2; P < .001). Notably, the change in LSBMD z-scores was significantly greater in high-dose versus standard-dose groups (median: +0.4 [IQR: -0.1 to +0.9] vs +0.1 [-0.4 to +0.7]; P = .02). Levels of 25(OH)D increased, whereas iPTH, CTX, and PINP declined significantly in both groups (P < .05), but no between-group differences were demonstrated. CONCLUSIONS: Over 48-week VitD/Ca supplementation, significant increases in LSBMD, and significant decreases in bone metabolism-related markers were observed among our Thai PHIVA in both treatment groups. The improvement in LSBMD z-score was more enhanced with high-dose VitD/Ca supplementation than standard-dose. High-dose VitD/Ca supplementation might be considered to promote bone health in this population. CLINICAL TRIALS REGISTRATION: NCT02426840.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sudjaritruk T, Bunupuradah T, Aurpibul L, et al. Impact of Vitamin D and Calcium Supplementation on Bone Mineral Density and Bone Metabolism Among Thai Adolescents With Perinatally Acquired Human Immunodeficiency Virus (HIV) Infection: A Randomized Clinical Trial. Clin Infect Dis. 2021. PMID: 34125899. doi:10.1093/cid/ciab547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。